Literature DB >> 23829532

Therapeutic targeting of non-coding RNAs.

Thomas C Roberts1, Matthew J A Wood.   

Abstract

ncRNAs (non-coding RNAs) are implicated in a wide variety of cellular processes, including the regulation of gene expression. In the present chapter we consider two classes of ncRNA: miRNAs (microRNAs) which are post-transcriptional regulators of gene expression and lncRNAs (long ncRNAs) which mediate interactions between epigenetic remodelling complexes and chromatin. Mutation and misexpression of ncRNAs have been implicated in many disease conditions and, as such, pharmacological modulation of ncRNAs is a promising therapeutic approach. miRNA activity can be antagonized with antisense oligonucleotides which sequester or degrade mature miRNAs, and expressed miRNA sponges which compete with target transcripts for miRNA binding. Conversely, synthetic or expressed miRNA mimics can be used to treat a deficiency in miRNA expression. Similarly, conventional antisense technologies can be used to silence lncRNAs. Targeting promoter-associated RNAs with siRNAs (small interfering RNAs) results in recruitment of chromatin-modifying activities and induces transcriptional gene silencing. Alternatively, targeting natural antisense transcripts with siRNAs or antisense oligonucleotides can abrogate endogenous epigenetic silencing leading to transcriptional gene activation. The ability to modulate gene expression at the epigenetic level presents exciting new opportunities for the treatment of human disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23829532     DOI: 10.1042/bse0540127

Source DB:  PubMed          Journal:  Essays Biochem        ISSN: 0071-1365            Impact factor:   8.000


  25 in total

Review 1.  Perspectives on the mechanism of transcriptional regulation by long non-coding RNAs.

Authors:  Thomas C Roberts; Kevin V Morris; Marc S Weinberg
Journal:  Epigenetics       Date:  2013-10-22       Impact factor: 4.528

2.  Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression.

Authors:  Andrew J Streets; Tajdida A Magayr; Linghong Huang; Laura Vergoz; Sandro Rossetti; Roslyn J Simms; Peter C Harris; Dorien J M Peters; Albert C M Ong
Journal:  Am J Physiol Renal Physiol       Date:  2017-01-11

Review 3.  Advances in therapeutic development for spinal muscular atrophy.

Authors:  Matthew D Howell; Natalia N Singh; Ravindra N Singh
Journal:  Future Med Chem       Date:  2014-06       Impact factor: 3.808

Review 4.  The role of long non-coding RNAs in neurodevelopment, brain function and neurological disease.

Authors:  Thomas C Roberts; Kevin V Morris; Matthew J A Wood
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-09-26       Impact factor: 6.237

Review 5.  Targeting noncoding RNAs in disease.

Authors:  Brian D Adams; Christine Parsons; Lisa Walker; Wen Cai Zhang; Frank J Slack
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

Review 6.  Novel insights into the interaction between long non-coding RNAs and microRNAs in glioma.

Authors:  Anahita Ebrahimpour; Mohammad Sarfi; Setareh Rezatabar; Sadra Samavarchi Tehrani
Journal:  Mol Cell Biochem       Date:  2021-02-13       Impact factor: 3.396

Review 7.  Emerging roles for ncRNAs in alcohol use disorders.

Authors:  R Dayne Mayfield
Journal:  Alcohol       Date:  2017-04-15       Impact factor: 2.405

Review 8.  Gene regulation of mammalian long non-coding RNA.

Authors:  Heeyoun Bunch
Journal:  Mol Genet Genomics       Date:  2017-09-11       Impact factor: 3.291

9.  Not so pseudo anymore: pseudogenes as therapeutic targets.

Authors:  Thomas C Roberts; Kevin V Morris
Journal:  Pharmacogenomics       Date:  2013-12       Impact factor: 2.533

Review 10.  Epigenetics and ncRNAs in brain function and disease: mechanisms and prospects for therapy.

Authors:  Miguel A Varela; Thomas C Roberts; Matthew J A Wood
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.